Methods of treatment using anti-CD3 antibodies
US7993641B2 · kind B2 · utility
48Cited by
6References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 16, 2006 |
| Grant date | Aug 9, 2011 |
| Priority date | — |
| Expiry date | Jul 26, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.